A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication

[1]  Patrick Neven,et al.  Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors , 2013, PLoS genetics.

[2]  A. Stang,et al.  Population-based hormone receptor-specific incidence trends of breast cancer in Germany. , 2012, Maturitas.

[3]  A. Trentham-Dietz,et al.  A Sustained Decline in Postmenopausal Hormone Use: Results From the National Health and Nutrition Examination Survey, 1999–2010 , 2012, Obstetrics and gynecology.

[4]  Peter Kraft,et al.  Challenges and opportunities in genome-wide environmental interaction (GWEI) studies , 2012, Human Genetics.

[5]  Peter Kraft,et al.  Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. , 2011, Journal of the National Cancer Institute.

[6]  A. Whittemore,et al.  Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study , 2010, Breast Cancer Research.

[7]  V. Beral,et al.  Gene-Environment Interactions in 7610 Women With Breast Cancer: Prospective Evidence From the Million Women Study , 2010 .

[8]  J. Manson,et al.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.

[9]  R. Eils,et al.  Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy , 2010, International journal of cancer.

[10]  M. Serrano,et al.  The TRIP from ULF to ARF. , 2010, Cancer cell.

[11]  R. Eils,et al.  Postmenopausal estrogen monotherapy–associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism , 2010, Breast Cancer Research and Treatment.

[12]  R. Eils,et al.  Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women , 2010, Breast Cancer Research and Treatment.

[13]  K. Kang,et al.  DNER modulates adipogenesis of human adipose tissue‐derived mesenchymal stem cells via regulation of cell proliferation , 2010, Cell proliferation.

[14]  D. Cox,et al.  Variation in the FGFR2 Gene and the Effects of Postmenopausal Hormone Therapy on Invasive Breast Cancer , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[15]  K. Matsuo,et al.  FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: Results of a case control study in Japan , 2009, International journal of cancer.

[16]  Alfredo Quinones-Hinojosa,et al.  DNER, an Epigenetically Modulated Gene, Regulates Glioblastoma‐Derived Neurosphere Cell Differentiation and Tumor Propagation , 2009, Stem cells.

[17]  Peter Kraft,et al.  The Impact of Gene-Environment Dependence and Misclassification in Genetic Association Studies Incorporating Gene-Environment Interactions , 2009, Human Heredity.

[18]  W. Willett,et al.  A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) , 2009, Nature Genetics.

[19]  Karen Canfell,et al.  Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003 , 2009, Breast Cancer Research and Treatment.

[20]  P. Kyyrönen,et al.  Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005. , 2008, Maturitas.

[21]  T. Rebbeck,et al.  Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. , 2008, Carcinogenesis.

[22]  Peter Kraft,et al.  Curses--winner's and otherwise--in genetic epidemiology. , 2008, Epidemiology.

[23]  J. Chang-Claude,et al.  Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy , 2008, International journal of cancer.

[24]  Jenny Chang-Claude,et al.  Gene–environment interactions for complex traits: definitions, methodological requirements and challenges , 2008, European Journal of Human Genetics.

[25]  Jenny Chang-Claude,et al.  Sample size requirements for indirect association studies of gene–environment interactions (G × E) , 2008, Genetic epidemiology.

[26]  A. Mueck,et al.  Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  J. Wiebe,et al.  Regulation of estrogen receptor (ER) levels in MCF-7 cells by progesterone metabolites , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[29]  J. Wiebe.  Progesterone metabolites in breast cancer. , 2006, Endocrine-related cancer.

[30]  J. Wiebe,et al.  Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[31]  G. Abecasis,et al.  Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies , 2006, Nature Genetics.

[32]  N. Shah,et al.  Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis , 2005, Menopause.

[33]  S. Gabriel,et al.  Efficiency and power in genetic association studies , 2005, Nature Genetics.

[34]  Christopher I. Li.  Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. , 2004, Maturitas.

[35]  L. Benet,et al.  P-glycoprotein (P-gp/MDR1)-Mediated Efflux of Sex-Steroid Hormones and Modulation of P-gp Expression In Vitro , 2004, Pharmaceutical Research.

[36]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[37]  P. Newcomb,et al.  Selection bias in the assessment of gene-environment interaction in case-control studies. , 2003, American journal of epidemiology.

[38]  P. Hartge,et al.  Joint effect of genes and environment distorted by selection biases: implications for hospital-based case-control studies. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[39]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[40]  W. Willett,et al.  Postmenopausal estrogen and progestin use in relation to breast cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  W James Gauderman,et al.  Sample size requirements for matched case‐control studies of gene–environment interaction , 2002, Statistics in medicine.

[42]  N. Kakazu,et al.  Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. , 2001, European journal of biochemistry.

[43]  M. Pike,et al.  Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. , 2000, Journal of the National Cancer Institute.

[44]  R. Hoover,et al.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. , 2000, JAMA.

[45]  H. Adami,et al.  Breast‐cancer risk following long‐term oestrogen‐ and oestrogen‐progestin‐replacement therapy , 1999, International journal of cancer.

[46]  B. Zumoff.  Does Postmenopausal Estrogen Administration Increase the Risk of Breast Cancer? Contributions of Animal, Biochemical, and Clinical Investigative Studies to a Resolution of the Controversy , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[47]  V. Beral,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[48]  T. Fojo,et al.  Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells , 1996 .

[49]  M. Poutanen,et al.  Role of 17β-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[50]  Jack A. Taylor,et al.  Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. , 1994, Statistics in medicine.

[51]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[52]  J. Chang-Claude,et al.  Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy , 2011, Breast Cancer Research and Treatment.

[53]  K. Horwitz,et al.  Estrogens and Progestins in Mammary Development and Neoplasia , 2004, Journal of Mammary Gland Biology and Neoplasia.

[54]  T. Fojo,et al.  Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. , 1996, Biochemistry.